Background/Aim: Advanced melanoma treatment remains debated, particularly in patients with B-Raf proto-oncogene serine/threonine kinase (BRAF) V600 mutations eligible for both immune checkpoint inhibitors (ICI) and BRAF/MEK inhibitors. Additional biomarkers are needed to improve treatment selection. Mutations of the te...
P. Marchese, Irene Zannini, D. de Biase et al.· Anticancer Research· 0 citations
Simple Summary Nevus-associated melanoma, a melanoma arising in association with a pre-existing melanocytic nevus, accounts for approximately one-quarter of all cutaneous melanomas and is usually diagnosed at an early stage. Although thin nevus-associated melanomas generally have an excellent prognosis, a small proport...
Federico Venturi, Maria Luisa Orlando, Barbara Corti et al.· Cancers· 0 citations
Cutaneous melanoma is a malignant tumor and remains a clinical challenge due to unmet needs in risk stratification, real-time treatment monitoring, and early detection of progression or resistance. Early detection is crucial, as prognosis significantly worsens once metastasis occurs. Liquid biopsy has emerged as a powe...
E. Broseghini, G. Durante, A. Soru et al.· Frontiers in Cell and Develo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
